Serum uric acid level and risk for peripheral arterial disease: Analysis of data from the multiple risk factor intervention trial

被引:75
作者
Baker, Joshua F.
Schumacher, H. Ralph
Krishnan, Eswar
机构
[1] Univ Pittsburgh, Dept Med, Div Rheumatol, Pittsburgh, PA 15261 USA
[2] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[3] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1177/0003319707303444
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Although several studies report an association between hyperuricemia and coronary artery disease, little is known about the effect of hyperuricemia and gout on the risk of peripheral arterial disease (PAD). Data on 283 incident clinical cases of PAD during a randomized controlled trial of multiple cardiovascular risk factor intervention are evaluated. The serum uric acid levels among these individuals are compared with those of individuals who did not develop PAD during the study period. Multivariate logistic regression analyses measure the risk of developing PAD associated with higher levels of serum uric acid after adjusting for the effect of traditional vascular risk factors. Age and smoking are independently associated with development of PAD, with odds ratios of 1.08 (95% confidence interval [CI], 1.06-1.09) and 3.83 (95% CI, 2.49-5.91) per year, respectively. Hyperuricemia (serum uric acid level, > 7.0 mg/dL) is an independent risk factor, with an odds ratio of 1.23, but the confidence interval of the estimate is wide (95% CI, 0.98-1.54). In this multivariate model, a history of gout was associated with an odds ratio of 1.33 (95% CI, 1.07-1.66). Serum uric acid level is independently associated with a higher (but statistically nonsignificant) risk of PAD. A history of gouty arthritis is an independent and statistically significant predictor of incidence of PAD even after adjustment for the effect of underlying hyperuricemia.
引用
收藏
页码:450 / 457
页数:8
相关论文
共 33 条
  • [1] Serum uric acid and cardiovascular events in successfully treated hypertensive patients
    Alderman, MH
    Cohen, H
    Madhavan, S
    Kivlighn, S
    [J]. HYPERTENSION, 1999, 34 (01) : 144 - 150
  • [2] Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging
    Anker, SD
    Doehner, W
    Rauchhaus, M
    Sharma, R
    Francis, D
    Knosalla, C
    Davos, CH
    Cicoira, M
    Shamim, W
    Kemp, M
    Segal, R
    Osterziel, KJ
    Leyva, F
    Hetzer, R
    Ponikowski, P
    Coats, AJS
    [J]. CIRCULATION, 2003, 107 (15) : 1991 - 1997
  • [3] [Anonymous], 1977, Journal of Chronic Diseases, V30, P261
  • [4] [Anonymous], 1979, JAMA
  • [5] Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
    Baker, JF
    Krishnan, E
    Chen, L
    Schumacher, HR
    [J]. AMERICAN JOURNAL OF MEDICINE, 2005, 118 (08) : 816 - 826
  • [6] Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease
    Bickel, C
    Rupprecht, HJ
    Blankenberg, S
    Rippin, G
    Hafner, G
    Daunhauer, A
    Hofmann, KP
    Meyer, J
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (01) : 12 - 17
  • [7] Uric acid and the vasculature
    Corry, Dalila B.
    Tuck, Michael L.
    [J]. CURRENT HYPERTENSION REPORTS, 2006, 8 (02) : 116 - 119
  • [8] ATHEROSCLEROSIS AND URATE METABOLISM
    EMMERSON, BT
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1979, 9 (04): : 451 - 454
  • [9] Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP)
    Franse, LV
    Pahor, M
    Di Bari, M
    Shorr, RI
    Wan, JY
    Somes, GW
    Applegate, WB
    [J]. JOURNAL OF HYPERTENSION, 2000, 18 (08) : 1149 - 1154
  • [10] RELEASE OF PLATELET CONSTITUENTS BY MONOSODIUM URATE CRYSTALS
    GINSBERG, MH
    KOZIN, F
    OMALLEY, M
    MCCARTY, DJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (05) : 999 - 1007